GSK-3β Inhibition Attenuates CLP-Induced Liver Injury by Reducing Inflammation and Hepatic Cell Apoptosis

Figure 4

GSK-3β inhibition modulates the NF-κB and CREB activation following CLP. Mice were subjected to CLP and treated with either SB216763 (25 mg/kg, i.p.) or vehicle (DMSO). Liver samples were harvested at 20 h after CLP. NF-κB activity, as well as CREB activity, was assessed. Data are shown as mean ± SD. per group. , ^# compared with vehicle-treated group.

(a)

(b)